548 related articles for article (PubMed ID: 33422979)
1. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
Urban M; Šlachtová V; Brulíková L
Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
[TBL] [Abstract][Full Text] [Related]
2. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
[TBL] [Abstract][Full Text] [Related]
3. Targeting Energy Metabolism in
Bald D; Villellas C; Lu P; Koul A
mBio; 2017 Apr; 8(2):. PubMed ID: 28400527
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the synthetic lethality between terminal respiratory oxidases to kill
Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents.
Bahuguna A; Rawat S; Rawat DS
Med Res Rev; 2021 Jul; 41(4):2565-2581. PubMed ID: 33400275
[TBL] [Abstract][Full Text] [Related]
8. Emerging opportunities of exploiting mycobacterial electron transport chain pathway for drug-resistant tuberculosis drug discovery.
Roy KK; Wani MA
Expert Opin Drug Discov; 2020 Feb; 15(2):231-241. PubMed ID: 31774006
[No Abstract] [Full Text] [Related]
9. New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis.
Lupien A; Foo CS; Savina S; Vocat A; Piton J; Monakhova N; Benjak A; Lamprecht DA; Steyn AJC; Pethe K; Makarov VA; Cole ST
PLoS Pathog; 2020 Jan; 16(1):e1008270. PubMed ID: 31971990
[TBL] [Abstract][Full Text] [Related]
10. ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines.
Saxena AK; Alam M
Curr Top Med Chem; 2020; 20(29):2723-2734. PubMed ID: 32885753
[TBL] [Abstract][Full Text] [Related]
11. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.
Lee BS; Hards K; Engelhart CA; Hasenoehrl EJ; Kalia NP; Mackenzie JS; Sviriaeva E; Chong SMS; Manimekalai MSS; Koh VH; Chan J; Xu J; Alonso S; Miller MJ; Steyn AJC; Grüber G; Schnappinger D; Berney M; Cook GM; Moraski GC; Pethe K
EMBO Mol Med; 2021 Jan; 13(1):e13207. PubMed ID: 33283973
[TBL] [Abstract][Full Text] [Related]
13. Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc
Kalia NP; Shi Lee B; Ab Rahman NB; Moraski GC; Miller MJ; Pethe K
Sci Rep; 2019 Jun; 9(1):8608. PubMed ID: 31197236
[TBL] [Abstract][Full Text] [Related]
14. A Novel Small-Molecule Inhibitor of the
Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D
mBio; 2017 Feb; 8(1):. PubMed ID: 28196957
[TBL] [Abstract][Full Text] [Related]
15. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
Ceska Slov Farm; 2021; 70(5):164-171. PubMed ID: 35114793
[TBL] [Abstract][Full Text] [Related]
16. Identification of 4-Amino-Thieno[2,3-
Harrison GA; Mayer Bridwell AE; Singh M; Jayaraman K; Weiss LA; Kinsella RL; Aneke JS; Flentie K; Schene ME; Gaggioli M; Solomon SD; Wildman SA; Meyers MJ; Stallings CL
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511370
[TBL] [Abstract][Full Text] [Related]
17. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
Saxena AK; Singh A
Curr Top Med Chem; 2019; 19(5):337-355. PubMed ID: 30806318
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
19. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
Ceska Slov Farm; 2021; 70(5):164–171. PubMed ID: 34875838
[TBL] [Abstract][Full Text] [Related]
20. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
